Video

Episode 5 - Setting the Tone: Current Therapeutic Goals

Appropriately managing the suite of cardiometabolic disorders has substantial clinical implications for cardiovascular health and prevention of cardiovascular disease (CVD). In the case of diabetes, dyslipidemias, and hypertension, achieving the goals of HbA1c <7%, LDL cholesterol <100 mg/dL, and blood pressure <140/90 sets the patient up with significant cardiovascular benefits, such as the prevention of downstream CVD, heart attack, heart failure, or stroke. Although there has always been a “disconnect” between what is known and what is actually done, on both clinician and patient levels, and at times, compromises have to be made to individualize treatments, there is still an awareness of the importance of managing the individual components of cardiometabolic disorders aggressively and effectively.


Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP)
Eileen Peng, PharmD, sitting for a video interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo